Etrasimod as Prevention of Pouchitis

Exclusion Criteria30

• Isolated cuffitis (verified at screening pouchoscopy)
• Diagnosis of Crohn's disease (verified at screening)
• Diagnosis of Crohn's disease-like pouch inflammation (verified at screening)
• o Crohn's disease-like pouch inflammation is defined as ulcerations of the pre-pouch ileum extending > 10 cm above the inlet, strictures in the pre-pouch ileum or pouch body outside of the anastomoses, and/or fistulae of the pre-pouch ileum, pouch body, or perineum
• Diagnosis of chronic pouchitis (verified at screening)
• o Chronic pouchitis is defined as persistent (> 4 weeks) or recurrent (> 4 episodes/year) symptoms of pouchitis
• Anastomotic stenosis or other mechanical complications of the pouch (verified at screening pouchoscopy)
• Treatment with probiotics ≤ 3 months prior to screening (verified at screening)
• Treatment with topical rectal 5-ASA, or steroids ≤ 2 weeks prior to or during screening (verified at screening)
• Any use of a biologic or small molecule approved for moderately to severely active UC or investigational, after TPC with IPAA (verified at screening)
• Any prior exposure to a S1P receptor modulator therapy, at any time (verified at screening)
• Any investigational or biologic agent within 30 days of screening pouchoscopy (verified at screening)
• Have the following cardiovascular history (verified at screening):
• In the last 6 months, have experienced a myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III or IV heart failure
• Have a history or presence of Mobitz type II second-degree or third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker
• A history of symptomatic bradycardia, recurrent cardiogenic syncope, Mobitz type I second-degree AV block, or severe untreated sleep apnea
• Significant QT prolongation (QTcF interval ≥ 450 ms in male or ≥ 470 ms in females)
• Arrhythmias requiring treatment with Class Ia or Class III anti-arrhythmic drugs or QT prolonging drugs
• Clinically significant or serious active infection ≤ 28 days prior to baseline - including but not limited to (verified at screening):
• Positive assay or stool culture for pathogens (ova and parasite examination, bacteria) or
• positive test for Clostridioides difficile toxin at screening
• Active tuberculosis
• Acute or chronic hepatitis B or hepatitis C
• HIV infection
• Pregnancy, lactation, or a positive urine pregnancy test measured during screening
• Severe hepatic impairment (Child Pugh Class C) (verified at screening)
• Have a known history of macular edema or retinopathy (verified at screening)
• History of cancer within the last 5 years (excluding in situ squamous or basal cell carcinoma of the skin that has been excised and resolved) or current malignancy (verified at screening)
• History of posterior reversible encephalopathy syndrome (PRES)
• Have a history of any clinically significant medical condition that, in the investigator's opinion, precludes participation in the study (verified at screening)